Safety and efficacy of autologous, adipose-derived mesenchymal stem cells in patients with rheumatoid arthritis: a phase I/IIa, open-label, non-randomized pilot trial

Table 2 Median, inter-quartile range and efficacy measures for joint counts and inflammatory parameters at baseline and week 52 post-intervention

Variable	Baseline Median (IQR)	Week 52 Median (IQR)	p value	Effect Size
Tender JC	20.0 (11.0–36.0)	1.00 (0.00–4.00)	0.0008^**	0.93
Swollen JC	12.0 (8.00–19.0)	1.00 (0.00–3.00)	0.003^*	0.83
CRP	10.0 (4.50–18.1)	6.00 (3.00–12.0)	0.183	0.37
ESR	43.0 (33.0–55.0)	34.5 (23.8–62.8)	0.775	0.05
IL-6	4.90 (2.90–12.1)	4.60 (2.75–13.9)	0.714	0.10
TNF-α	1.45 (0.88–3.23)	1.15 (0.73–2.28)	0.743	0.09

JC, joint count; TNF-α, tumor necrosis factor-alpha; IL-6, interleukin-6; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; IQR, interquartile range (25%—75%)
^*p < 0.01 and **p < 0.001 (Wilcoxon-signed rank test; Holm-Šídák correction for multiple comparisons). ES = Effect Size (Rosenthal’s formula with N = 13; one subject had data out to week 26 and one had data out to week 12)

ISSN: 1757-6512